

Fabio Valenti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2921295/publications.pdf>

Version: 2024-02-01

8
papers

645
citations

1163117
8
h-index

1588992
8
g-index

8
all docs

8
docs citations

8
times ranked

1230
citing authors

#	ARTICLE	IF	CITATIONS
1	Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. <i>Lancet Neurology</i> , The, 2011, 10, 320-328.	10.2	222
2	<scp>YAP</scp> enhances the pro-proliferative transcriptional activity of mutant p53 proteins. <i>EMBO Reports</i> , 2016, 17, 188-201.	4.5	154
3	Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. <i>Cell Cycle</i> , 2011, 10, 4330-4340.	2.6	74
4	Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma. <i>Theranostics</i> , 2018, 8, 1850-1868.	10.0	65
5	Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression. <i>Oncotarget</i> , 2015, 6, 5547-5566.	1.8	41
6	Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease. <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 105-117.	5.0	33
7	The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas. <i>Cancers</i> , 2019, 11, 1347.	3.7	31
8	Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. <i>Neuromuscular Disorders</i> , 2014, 24, 1003-1017.	0.6	25